|
| |
| | | 67501 | | 10.05.2020 | | Pfizer AG | | | | | | | | | | | | | 07.16.10. | | | | 07.16.10. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Zirabev 100 mg/4 ml | Konzentrat zur Herstellung einer Infusionslösung | Concentrate for infusion (Bevacizumab 100mg / 4ml) | L01FG01 | | | 02 | Zirabev 400 mg/16 ml | Konzentrat zur Herstellung einer Infusionslösung | Concentrate for infusion (Bevacizumab 400mg / 16ml) | L01FG01 | |
|
|
|
